100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43MH119672
Award Date
9/14/18
Completion Date
9/13/20
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Institute of Mental Health
Awardee
Biomedical Development Corp (CATLLUJNR7W4)
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Update #1
Update #2
MHEALTH FOR PATIENT SELF-MANAGEMENT OF OPIOID USE DISORDER
Posted 9/14/18
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
MHEALTH FOR PATIENT SELF-MANAGEMENT OF OPIOID USE DISORDER - OPIOID ABUSE HAS BECOME AN EPIDEMIC WITH DEVASTATING HEALTH, SOCIAL, AND ECONOMIC CONSEQUENCES FOR THE UNITED STATES. DRUG OVERDOSE DEATHS HAVE NEARLY TRIPLED FROM 1999-2014. DURING 2015, DRUG OVERDOSES ACCOUNTED FOR 52,404 U.S. DEATHS, INCLUDING 33,091 (63.1%) THAT INVOLVED AN OPIOID (OPIOID PAIN RELIEVERS AND HEROIN). OPIOID ANALGESIC OVERDOSE IS NOW THE LEADING CAUSE OF INJURY DEATH IN THE U.S; IN 2014, THERE WERE APPROXIMATELY ONE AND A HALF TIMES MORE DRUG OVERDOSE DEATHS THAN DEATHS FROM MOTOR VEHICLE ACCIDENTS. TREATMENT FOR AN OPIOID USE DISORDER (OUD) IS A COMPLEX MULTIFACTORIAL PROCESS OFTEN INVOLVING MEDICATION ASSISTED TREATMENT (MAT) AND REQUIRING CHANGES IN DEEPLY IMBEDDED BEHAVIORS. PATIENTS ARE TREATED IN THE CLINIC, BUT FIGHT ADDICTION IN THEIR DAILY LIVES. RATES OF RELAPSE ARE HIGH, AND ACCESS TO SUPPORTIVE CARE IS LIMITED AND COSTLY. TREATMENT APPROACHES MUST BE TAILORED TO ADDRESS EACH PATIENT'S DRUG USE PATTERNS AND DRUGRELATED MEDICAL, PSYCHIATRIC, AND SOCIAL PROBLEMS. WHILE A FEW ONLINE TOOLS EXIST TO ASSIST PATIENTS IN THEIR RECOVERY, CURRENT PRODUCTS OFFER ONLY GENERALIZED INFORMATION THAT MAY OR MAY NOT BE RELEVANT AND TIMELY, OR ACT SOLELY AS SUPPORTIVE SOCIAL NETWORKING SERVICES. IN PREVIOUS WORK, WE DEVELOPED KIOS, AN INNOVATIVE SOFTWARE PLATFORM DERIVED FROM NONLINEAR CONTROL THEORY. KIOS TRACKS MULTIPLE INTERACTING SYMPTOMS TO MAP PATIENT TRAJECTORIES AND DELIVER EVIDENCE-BASED INTERVENTION STRATEGIES RESPONSIVE TO THE SPECIFIC NEEDS OF INDIVIDUALS. ACCESSIBLE VIA COMPUTER OR MOBILE DEVICES, KIOS PROVIDES PATIENTS REAL TIME ADVICE AND REINFORCEMENT OF LIFESTYLE INTERVENTIONS TO IMPROVE SELFMANAGEMENT. KIOS ALSO CAN PROVIDE BETWEEN-VISIT REPORTING TO CLINICIANS VIA DOWNLOADABLE REPORTS OR DIRECT ONLINE MONITORING. THEREFORE, THE GOAL OF THIS PROJECT IS TO ADAPT KIOS TO PATIENTS WITH AN OPIOID USE DISORDER. THE DEVELOPMENT OF THIS INNOVATIVE TOOL TO HELP PATIENTS MANAGE OUD HAS THE POTENTIAL TO HAVE A PROFOUND IMPACT ON PUBLIC HEALTH AND ACHIEVE SIGNIFICANT COMMERCIAL SUCCESS. THIS PHASE I SBIR STUDY HAS TWO SPECIFIC AIMS: SPECIFIC AIM 1: IDENTIFY PATIENT TRAJECTORIES OF OUD AND LINK EXPERT ADVICE TO CHANGING PATIENT STATES SPECIFIC AIM 2: BUILD USER INTERFACES AND TEST FEASIBILITY IN PATIENTS WITH OUD
$0
3/25/21
Not listed
MHEALTH FOR PATIENT SELF-MANAGEMENT OF OPIOID USE DISORDER - OPIOID ABUSE HAS BECOME AN EPIDEMIC WITH DEVASTATING HEALTH, SOCIAL, AND ECONOMIC CONSEQUENCES FOR THE UNITED STATES. DRUG OVERDOSE DEATHS HAVE NEARLY TRIPLED FROM 1999-2014. DURING 2015, DRUG OVERDOSES ACCOUNTED FOR 52,404 U.S. DEATHS, INCLUDING 33,091 (63.1%) THAT INVOLVED AN OPIOID (OPIOID PAIN RELIEVERS AND HEROIN). OPIOID ANALGESIC OVERDOSE IS NOW THE LEADING CAUSE OF INJURY DEATH IN THE U.S; IN 2014, THERE WERE APPROXIMATELY ONE AND A HALF TIMES MORE DRUG OVERDOSE DEATHS THAN DEATHS FROM MOTOR VEHICLE ACCIDENTS. TREATMENT FOR AN OPIOID USE DISORDER (OUD) IS A COMPLEX MULTIFACTORIAL PROCESS OFTEN INVOLVING MEDICATION ASSISTED TREATMENT (MAT) AND REQUIRING CHANGES IN DEEPLY IMBEDDED BEHAVIORS. PATIENTS ARE TREATED IN THE CLINIC, BUT FIGHT ADDICTION IN THEIR DAILY LIVES. RATES OF RELAPSE ARE HIGH, AND ACCESS TO SUPPORTIVE CARE IS LIMITED AND COSTLY. TREATMENT APPROACHES MUST BE TAILORED TO ADDRESS EACH PATIENT'S DRUG USE PATTERNS AND DRUGRELATED MEDICAL, PSYCHIATRIC, AND SOCIAL PROBLEMS. WHILE A FEW ONLINE TOOLS EXIST TO ASSIST PATIENTS IN THEIR RECOVERY, CURRENT PRODUCTS OFFER ONLY GENERALIZED INFORMATION THAT MAY OR MAY NOT BE RELEVANT AND TIMELY, OR ACT SOLELY AS SUPPORTIVE SOCIAL NETWORKING SERVICES. IN PREVIOUS WORK, WE DEVELOPED KIOS, AN INNOVATIVE SOFTWARE PLATFORM DERIVED FROM NONLINEAR CONTROL THEORY. KIOS TRACKS MULTIPLE INTERACTING SYMPTOMS TO MAP PATIENT TRAJECTORIES AND DELIVER EVIDENCE-BASED INTERVENTION STRATEGIES RESPONSIVE TO THE SPECIFIC NEEDS OF INDIVIDUALS. ACCESSIBLE VIA COMPUTER OR MOBILE DEVICES, KIOS PROVIDES PATIENTS REAL TIME ADVICE AND REINFORCEMENT OF LIFESTYLE INTERVENTIONS TO IMPROVE SELFMANAGEMENT. KIOS ALSO CAN PROVIDE BETWEEN-VISIT REPORTING TO CLINICIANS VIA DOWNLOADABLE REPORTS OR DIRECT ONLINE MONITORING. THEREFORE, THE GOAL OF THIS PROJECT IS TO ADAPT KIOS TO PATIENTS WITH AN OPIOID USE DISORDER. THE DEVELOPMENT OF THIS INNOVATIVE TOOL TO HELP PATIENTS MANAGE OUD HAS THE POTENTIAL TO HAVE A PROFOUND IMPACT ON PUBLIC HEALTH AND ACHIEVE SIGNIFICANT COMMERCIAL SUCCESS. THIS PHASE I SBIR STUDY HAS TWO SPECIFIC AIMS: SPECIFIC AIM 1: IDENTIFY PATIENT TRAJECTORIES OF OUD AND LINK EXPERT ADVICE TO CHANGING PATIENT STATES SPECIFIC AIM 2: BUILD USER INTERFACES AND TEST FEASIBILITY IN PATIENTS WITH OUD
$0
3/25/21
Not listed
MHEALTH FOR PATIENT SELF-MANAGEMENT OF OPIOID USE DISORDER
$225.0k
9/14/18